Back to search results

FH-FOLR1 Chimeric Antigen Receptor T Cell Therapy for Treating Pediatric Patients With Relapsed or Refractory Acute Myeloid Leukemia

Abroad (travel likely)RecruitingPHASE1

Conditions

Recurrent Childhood Acute Myeloid Leukemia · Refractory Childhood Acute Myeloid Leukemia

Simple summaryAI-assisted

This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.

Locations

  • Fred Hutch/University of Washington/Seattle Children's Cancer Consortium, Seattle, Washington, United States

    Contact: Study coordinator (Katherine G. Tarlock, MD) · katherine.tarlock@seattlechildrens.org · 206-667-7121
    Contact: Principal Investigator (Katherine G. Tarlock, MD)
Study leads

  • Katherine G. Tarlock, MD

    Principal Investigator

    Fred Hutch/University of Washington/Seattle Children's Cancer Consortium

View source on ClinicalTrials.gov(opens in a new tab)